Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 2,500 shares, a decline of 44.4% from the March 15th total of 4,500 shares. Based on an average daily trading volume, of 20,400 shares, the short-interest ratio is currently 0.1 days.

Apollomics Trading Down 22.8 %

Shares of APLMW opened at $0.01 on Thursday. The business’s 50-day moving average is $0.01 and its 200-day moving average is $0.01. Apollomics has a fifty-two week low of $0.01 and a fifty-two week high of $0.03.

About Apollomics

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.